How to Structure Your Prescriber Relationship Under the New Rules

We hear this a lot right now. A beauty therapist or aesthetic practitioner who has been injecting safely for years, working with a prescriber they've never actually met in person, suddenly being told that arrangement is no longer legally compliant. It's stressful, it feels unfair, and for many people it puts their entire business model in question.

So let's work through it properly.

What changed and why

On 1 June 2025 the Nursing and Midwifery Council introduced a straightforward but significant rule: nurse and midwife prescribers must now conduct a physical, face-to-face consultation with a patient before prescribing any prescription-only medicine for an elective cosmetic procedure. That includes botulinum toxin. That includes dermal fillers. Any prescription-only Amber-tier treatment.

The remote prescribing model — where a prescriber would review photos or jump on a video call and then authorise a prescription — is no longer compliant under any of the major professional regulatory boards. This applies equally to the prescriber and to the clinic using them. It's not a grey area and it's not something you can argue around.

The intention behind the rule is straightforward. If a prescriber is issuing a prescription, they need to have actually assessed the patient. That means being in the room.

What "clinical oversight" actually means now

Under the confirmed framework for Amber-tier procedures, a non-prescribing practitioner can still legally perform injectable treatments. But the prescribing healthcare professional — your named prescriber — must physically perform the patient assessment and maintain ongoing clinical responsibility for that patient's treatment plan.

This is what "clinical oversight" means in practice. It is not a prescriber signing a form. It is not a prescriber reviewing notes remotely. It is a prescriber who has physically seen the patient, made a clinical assessment and taken responsibility for the prescription they are issuing.

For many clinics that currently work with remote prescribers, this means the relationship needs to be rebuilt from the ground up.

Finding and contracting with an on-site prescriber

The first challenge is finding a prescriber who can work on this basis. What you're looking for is a qualified healthcare professional — a doctor, prescribing nurse, prescribing midwife or pharmacist independent prescriber — who holds an accredited prescribing qualification and is willing to provide on-site clinical oversight for your clinic's Amber treatments.

Some clinics hire a prescriber as a part-time employee. Others work with prescribers on a sessional or retainer basis, where the prescriber attends for specific treatment days or blocks. Neither model is inherently better. What matters is that the arrangement is formalised in writing.

You need an Associate Agreement that clearly sets out a few key things: what procedures the prescriber is authorising, how clinical responsibility is defined between you, what the supervision boundaries are and how liability is handled if something goes wrong. This is not a document to draft yourself. A solicitor with healthcare experience is worth the cost here because vicarious liability in clinical settings is genuinely complicated.

The logistics of making it work

The most common concern we hear is cost. Bringing a prescriber on-site for every treatment day adds overhead that remote prescribing did not. That's a real business challenge and there's no point pretending otherwise.

A few things that can help: block-booking prescriber sessions around your injectable appointment days rather than running them ad hoc; grouping your Amber consultations so the prescriber sees multiple patients in a single session; and being transparent with clients that the face-to-face prescriber consultation is part of the service they're receiving. Many clients, when it's explained properly, view it as a quality marker rather than an inconvenience.

The other logistics point worth flagging is documentation. Every single Amber treatment needs an auditable trail that links it to the prescriber's physical consultation. That means the date of the consultation, the prescriber's name and credentials, what was assessed and what was prescribed. This needs to be stored and retrievable. If a local authority Environmental Health Officer asks to see it, "it's in an email somewhere" is not a sufficient answer.

The bottom line

This change is disruptive. There's no version of this where the transition from remote to on-site prescribing is painless for every clinic. But the practitioners who adapt now and build a properly structured prescriber relationship are the ones who will be in the strongest position when local authority licensing comes into force.

The ones who try to work around it, or who assume their existing remote arrangement is close enough, are carrying a compliance risk that could invalidate their professional indemnity insurance and expose them to regulatory investigation.

It's worth getting right.

Complyable is built to make the on-site prescriber model operationally simple. The platform's dual-authorisation workflow means an Amber treatment log cannot be closed until the named prescriber inputs their digital PIN and confirms the face-to-face consultation on record. No paperwork. No chasing signatures. A clean, auditable trail that proves compliance at every appointment. Join the waitlist at getcomplyable.co.uk.